Non-Alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Others), By End-Use (Pharma and CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Non-Alcoholic Steatohepatitis Biomarkers Market Size

The global non-alcoholic steatohepatitis biomarkers market size was valued at USD 1.76 billion in 2025 and is projected to grow from USD 2.16 billion in 2026 to USD 11.18 billion by 2034, registering a CAGR of 22.8% during the forecast period from 2026 to 2034. North America dominated the non-alcoholic steatohepatitis biomarkers market with a market share of 38% in 2025.

The global prevalence of NASH is increasing as the prevalence of obesity, metabolic syndrome, and diabetes rises, promoting market growth. Non-alcoholic steatohepatitis (NASH) biomarkers are biological indicators used in the medical field to identify, diagnose, and track the evolution of NASH, a severe form of non-alcoholic fatty liver disease (NAFLD). These biomarkers are critical in assessing liver health, detecting the extent of liver damage, and directing therapy options.

Non-alcoholic steatohepatitis biomarkers market share is increasing due to increased chronic liver disease prevalence, which is expected to drive demand for non-invasive diagnostic techniques for NASH diagnosis. Furthermore, the industry is growing due to the introducing of new diagnostic tests.

Segmentation Analysis

By Type

The market is further segmented into Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, and Oxidative Stress Biomarkers. The Serum Biomarkers segment mostly influences the market growth. serum biomarkers are blood-based markers detected with a simple blood test. They frequently represent bloodstream chemicals and can reflect various aspects of liver health. The segment's dominance is related to the effectiveness and widespread use of serum biomarkers as a NASH diagnostic tool. Furthermore, its ability to distinguish between basic steatosis and NASH offers it a competitive advantage. The anticipated release of novel blood biomarkers such as apolipoprotein B, apolipoprotein A1, leptin, adiponectin, ghrelin, free fatty acids, and tumor necrosis factor-alpha will drive market expansion. Furthermore, prominent market participants are focusing on obtaining approvals for marketing serum biomarker-based tests to address the demand for diagnostic tools.

Apoptosis biomarkers are associated with the process of apoptosis, also known as programmed cell death. These indicators are linked to liver cell death in the context of NASH. Multiple studies have shown that apoptotic markers assist in discriminating between NASH and basic steatosis, which increases the population's acceptance of apoptosis biomarkers.

Request Customizationto receive a tailored report.

By End-Use

The market can be bifurcated into the Pharma and CRO Industry, Hospitals, Diagnostic Labs, and Academic Research Institutes. Pharma and CRO Industries hold the major market share. Clinical trials and research related to NASH drug development are frequently conducted in collaboration between the pharmaceutical industry and Contract Research Organizations (CROs). Biomarkers are crucial in these endeavors. The rising frequency of liver illnesses drives demand for non-invasive diagnostic methods to diagnose chronic liver disease, driving market growth. Furthermore, as diagnostics improve, the treatment market expands, increasing demand for pharmaceutical medications and fueling the entire segment's growth.

Diagnostic laboratories specialize in performing a wide range of medical tests, including those for liver illnesses such as NASH. They are in charge of evaluating patient samples and producing biomarker data. Over the projection period, the end-use category of diagnostic laboratories is expected to increase profitably. The expansion of diagnostic laboratories is due to increased public awareness of diagnosing Nonalcoholic fatty liver disease and NASH. Furthermore, as the number of items for diagnosis laboratories grows, they are gaining acceptance worldwide.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America: Dominant Region with A Significant Market Share

North America is the most significant global market shareholder. North America will grow tremendously, owing to increased diagnosis rates and the early launch of novel medicines in this area. Biomarker research and development funding is plentiful, which supports pharmaceutical development initiatives and promotes corporate growth. Furthermore, North America has a robust regulatory framework and reimbursement rules that encourage using biomarker-based diagnostics in clinical practice. The increasing mobility of players and the increased availability of tests in the US market are important factors driving the industry. For example, in January 2022, the FDA granted a De Novo marketing clearance to the ELF Test, a predictive blood test for evaluating disease development in NASH patients. The test is provided through a partnership between Quest Diagnostics and LabCorp. This provides physicians with rapid access to the test, allowing them to determine the possibility of a severe form of the condition.

On the other hand, the North American NASH biomarkers market is confronted with the issue of harmonizing diagnostic criteria and verifying biomarker panels. However, given its superior healthcare infrastructure and research skills, the region provides substantial prospects for biomarker development and tailored therapy in NASH.

Europe is anticipated to exhibit a healthy CAGR over the forecast period. The increased disease burden and the economic effect of NASH in the region drive non-alcoholic steatohepatitis biomarkers market growth. According to The European Journal of Health Economics in 2021, NASH diagnosis is frequently accidental as a result of a normal visit to the GP. However, 79.8% of the population goes undiagnosed, signifying a large opportunity and unmet need due to a lack of understanding about the condition's symptoms. The European Association for the Study of the Liver (EASL) and other regional organizations have produced NASH diagnosis and management guidelines, emphasizing the use of biomarkers in the clinical approach. Many clinical trials for NASH medication development are held in Europe, and biomarkers are used for patient selection and therapy monitoring. Pharmaceutical businesses in the region are making significant investments in NASH therapy.

The Asia-Pacific market for non-alcoholic steatohepatitis biomarkers is predicted to develop the fastest during the projection period. As obesity is becoming more prevalent, more people are becoming sedentary, and eating habits are changing. Furthermore, patients and healthcare providers are becoming more aware of the importance of early detection and management of NASH. As a result, biomarker-based diagnostics are becoming increasingly popular in this field. Furthermore, China's market for non-alcoholic steatohepatitis biomarkers had the greatest market share, while India's market for non-alcoholic steatohepatitis biomarkers was the Asia-Pacific region's fastest-expanding market.

Latin America, the Middle East and Africa all confront similar issues, such as limited access to healthcare resources and the need for specialized methods of NASH treatment, according to global non-alcoholic steatohepatitis biomarkers market insights. These places, however, provide considerable prospects for early identification and intervention via biomarkers, and they contribute to worldwide efforts to battle NASH.

Unlock Regional Insightsto access country-level data, & regional trends.

List of Key and Emerging Players in Non-Alcoholic Steatohepatitis Biomarkers Market